Skip to main content


The latest research in type 1 diabetes, type 2 diabetes, prediabetes, and beyond. Here you’ll find information on experimental therapies, new data and results, and scientific findings.

What's new

Are people aware of the link between diabetes and heart health? Do they know that certain diabetes drugs may protect the heart? Is heart health commonly discussed with healthcare professionals? We wanted to find out! Continue Reading »

For now, another SGLT-2 inhibitor pill already approved for people with type 2 diabetes is not approved for people with type 1 diabetes in the US. The drug was recently approved for type 1 diabetes in Europe and Japan Continue Reading »

Virta’s program resulted in “reversal” of type 2 diabetes in 54% of participants after two years. Data show 10% bodyweight loss, 0.9% A1C reduction, and reduced need for insulin and diabetes medications Continue Reading »

The first GLP-1 pill for type 2 diabetes offers weight loss and A1C reduction without injections; US decision expected in September 2019, EU decision expected spring of 2020 Continue Reading »

ADA 2019 diabetes day 4 5

Big focus on heart health outcome trials with PIONEER 6 and CAROLINA in the spotlight; plus promising CGM data in adolescents with type 1 diabetes Continue Reading »

The EMA approved Zynquista (sotagliflozin), an SGLT-1/2 dual inhibitor, for adults with a BMI above 27 Continue Reading »

Results from the CREDENCE trial suggest that Invokana’s kidney benefits exist on top of blood pressure lowering medications (standard of care) Continue Reading »

A huge milestone that makes Forxiga the first pill for people with type 1 diabetes in Europe Continue Reading »